| . | . | N (%) . |
|---|---|---|
| Atrial septal defect | Extension | 11 (36.7%) |
| Creation | 6 (20%) | |
| Left untouched | 13 (43.3%) | |
| Pulmonary venous | Treated autologous pericardium | 19 (63.3%) |
| pathway | Bovine pericardium | 6 (20%) |
| Right atrial freewall | 2 (6.7%) | |
| 0.6 mm thickness PTFE patcha | 2 (6.7%) | |
| 0.1 mm thickness PTFE membranea | 1 (3.3%) | |
| Systemic venous | Direct implantation | 20 (66.7%) |
| pathway | Patch augmentation of anterior walla,b | 6 (20%) |
| Right atrial wall pedicled flap | 3 (10%) | |
| PTFE tube grafta,c | 1 (3.3%) |
| . | . | N (%) . |
|---|---|---|
| Atrial septal defect | Extension | 11 (36.7%) |
| Creation | 6 (20%) | |
| Left untouched | 13 (43.3%) | |
| Pulmonary venous | Treated autologous pericardium | 19 (63.3%) |
| pathway | Bovine pericardium | 6 (20%) |
| Right atrial freewall | 2 (6.7%) | |
| 0.6 mm thickness PTFE patcha | 2 (6.7%) | |
| 0.1 mm thickness PTFE membranea | 1 (3.3%) | |
| Systemic venous | Direct implantation | 20 (66.7%) |
| pathway | Patch augmentation of anterior walla,b | 6 (20%) |
| Right atrial wall pedicled flap | 3 (10%) | |
| PTFE tube grafta,c | 1 (3.3%) |
N: number of patients; PTFE: polytetrafluoroethylene.
a PTFE (GoreTex; W.L. Gore & Associates, Inc., Newark, USA).
b Treated autologous pericardium in 2, bovine pericardium in 2 and 0.1 mm thickness PTFE membrane in 2.
c Early mortality.
| . | . | N (%) . |
|---|---|---|
| Atrial septal defect | Extension | 11 (36.7%) |
| Creation | 6 (20%) | |
| Left untouched | 13 (43.3%) | |
| Pulmonary venous | Treated autologous pericardium | 19 (63.3%) |
| pathway | Bovine pericardium | 6 (20%) |
| Right atrial freewall | 2 (6.7%) | |
| 0.6 mm thickness PTFE patcha | 2 (6.7%) | |
| 0.1 mm thickness PTFE membranea | 1 (3.3%) | |
| Systemic venous | Direct implantation | 20 (66.7%) |
| pathway | Patch augmentation of anterior walla,b | 6 (20%) |
| Right atrial wall pedicled flap | 3 (10%) | |
| PTFE tube grafta,c | 1 (3.3%) |
| . | . | N (%) . |
|---|---|---|
| Atrial septal defect | Extension | 11 (36.7%) |
| Creation | 6 (20%) | |
| Left untouched | 13 (43.3%) | |
| Pulmonary venous | Treated autologous pericardium | 19 (63.3%) |
| pathway | Bovine pericardium | 6 (20%) |
| Right atrial freewall | 2 (6.7%) | |
| 0.6 mm thickness PTFE patcha | 2 (6.7%) | |
| 0.1 mm thickness PTFE membranea | 1 (3.3%) | |
| Systemic venous | Direct implantation | 20 (66.7%) |
| pathway | Patch augmentation of anterior walla,b | 6 (20%) |
| Right atrial wall pedicled flap | 3 (10%) | |
| PTFE tube grafta,c | 1 (3.3%) |
N: number of patients; PTFE: polytetrafluoroethylene.
a PTFE (GoreTex; W.L. Gore & Associates, Inc., Newark, USA).
b Treated autologous pericardium in 2, bovine pericardium in 2 and 0.1 mm thickness PTFE membrane in 2.
c Early mortality.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
